240) The model group received no dalteparin, while the other 2 groups received dalteparin at 100 and 200 U/kg d, respectively. |
PMID:23965336 DOI:10.1177/1076029613499818 |
2015 Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis |
* Effect of dalteparin on atherosclerotic lesion formation in apolipoprotein E-deficient mice. |
- We aimed to investigate whether prolonged treatment with dalteparin could inhibit plaque progression. With C57BL/6J mice as the control, genetically deficient apolipoprotein E (apo E) male mice of C57BL/6J strain (apo E(-/-)) were randomly divided into 3 groups. The model group received no dalteparin, while the other 2 groups received dalteparin at 100 and 200 U/kg d, respectively. The aorta was harvested for hematoxylin and eosin staining to observe plaque formation and for immunohistochemical staining to detect the expression of oxidized low-density lipoprotein receptor 1 (LOX-1). The expression of LOX-1 messenger RNA was detected by reverse transcription polymerase chain reaction, while the expression of LOX-1 protein was detected by Western blotting. Dalteparin decreased aortic plaque volume and inhibited aortic LOX-1 protein expression in apo E(-/-) mice. The effect persisted 4 weeks after dalteparin treatment was discontinued. Dalteparin may inhibit atherosclerotic lesions by downregulating the expression of LOX-1 protein. |
(1)49 *null* | (15)7 received | (29)3 II | (44)2 difference |
(2)33 was | (16)5 at | (30)3 after | (45)2 displayed |
(3)29 and | (17)5 for | (31)3 comprised | (46)2 dynamics-based |
(4)25 of | (18)5 the | (32)3 in | (47)2 exhibited |
(5)16 compared | (19)5 to | (33)3 when | (48)2 however, |
(6)12 A | (20)4 (p | (34)2 (30 | (49)2 improved |
(7)12 were | (21)4 B | (35)2 (n | (50)2 included |
(8)11 discussions | (22)4 C | (37)2 B, | (51)2 intervention |
(9)10 than | (23)4 differences | (38)2 III | (52)2 interventions |
(10)9 I | (24)4 or | (39)2 V | (53)2 interviews |
(11)8 had | (25)3 1, | (40)2 a | (54)2 patients |
(12)8 showed | (26)3 2 | (41)2 as | (55)2 presented |
(13)8 with | (27)3 4 | (42)2 contains | (56)2 that |
(14)7 1 | (28)3 A, | (43)2 demonstrated |
add keyword